Human Mixtard 30/70 Injection 40 IU 10ml Vial

Human Mixtard 30/70 Injection 40 IU 10ml is used to improve low blood sugar in type 1 and type 2 diabetes in both adults and children. The medicine contains two drugs, Insulin Isophane (70%) + Human insulin (30%), which belongs to the group of antidiabetic agents (Insulin) used for hormone replacement therapy to regulate blood glucose level. It contains insulin that promotes glucose uptake into muscle and fat cells, inhibiting glucose production by the liver. A doctor's prescription is highly required in the treatment to enhance the effectiveness of the medicine.

• Improve blood sugar level

Every medication contains some acute and mild side effects, such as Human Mixtard 30/70 Injection cause certain symptoms that are manageable in some patients but some need proper medical attention to treat. Common ones include:

• Low blood sugar (Hypoglycaemia)
• Lightheadedness
• Dizziness
• Anxiety
• Nervousness
• Tiredness
• Feeling hungry
• Visual disturbances
• Headache
• Shaking
• Sweating
• Pale skin
• Skin rashes
• Pain, redness, swelling at the injection site.

Human Mixtard 30/70 Injection 40 IU 10ml should be taken on the thigh, upper arms, abdomen, and buttocks by a doctor or nurse. The medication can be used before or after a meal to help control blood sugar levels effectively, and the injection site should be rotated regularly to prevent skin problems such as lipodystrophy or irritation. Do not self-administer the medication; the correct dosage and duration are administered by the healthcare professional only. Follow the recommended dosage as prescribed to improve the effectiveness of the medication.

Blood sugar is caused by imbalances in glucose regulation, which can result in problems with production, insulin action, or both. When the body does not produce insulin, glucose cannot efficiently enter the cells, leading to higher blood pressure. Human Mixtard 30/70 Injection 40 IU 10ml helps to manage the blood sugar level in diabetic patients in both type 1 and type 2.

• Lauritzen, T., Pramming, S., Gale, E. A., Deckert, T., & Binder, C. (1982). Absorption of isophane (NPH) insulin and its clinical implications. Br Med J (Clin Res Ed), 285(6336), 159-162. https://pubmed.ncbi.nlm.nih.gov/6807390/
• Chandler, C., Gryniewicz, C. M., Pringle, T., & Cunningham, F. (2008). Insulin temperature and stability under simulated transit conditions. American Journal of Health-System Pharmacy, 65(10), 953-963. https://pubmed.ncbi.nlm.nih.gov/18463345/
• Tunbridge, F. K., Newens, A., Home, P. D., Davis, S. N., Murphy, M., Burrin, J. M., ... & Jensen, I. (1989). Double-blind crossover trial of isophane (NPH)-and lente-based insulin regimens. Diabetes Care, 12(2), 115-119. https://pubmed.ncbi.nlm.nih.gov/2649324/
• Owens, D. R., Jones, I. R., Birtwell, A. J., Burge, C. T. R., Luzio, S., Davies, C. J., ... & Heding, L. G. (1984). Study of porcine and human isophane (NPH) insulins in normal subjects. Diabetologia, 26(4), 261-265. https://pubmed.ncbi.nlm.nih.gov/6376233/
• Henriksen, J. E., Vaag, A., Hansen, I. R., Lauritzen, M., Djurhuus, M. S., & Beck‐Nielsen, H. (1991). Absorption of NPH (isophane) insulin in resting diabetic patients: evidence for subcutaneous injection in the thigh as the preferred site. Diabetic medicine, 8(5), 453-457. https://pubmed.ncbi.nlm.nih.gov/1830531/